

Research Associate – Process Development

Responsibilities

- Support internal research efforts by following internal SOPs to perform mammalian cell culture and cell encapsulation
- Collaborate with other scientists to establish critical process parameters for drug substance and drug product
- Make detailed observations and maintain a laboratory notebook
- Assist with the design and execution of experiments to optimize procedures for project advancement using statistical analysis
- Draft SOPs and present data in cross functional meetings
- Support lab functions-including, but not limited to restocking consumables, maintaining equipment, and cleaning
- Practice good aseptic sterile technique and comply with standard laboratory practices
- Reports into the Process Engineering team at Avenge Bio

Preferred Qualifications

- BS or MS degree in biological, chemical, materials, or mechanical engineering or relevant field
- Attention to detail, critical analysis of data, and troubleshooting abilities
- Highly collaborative working style, and ability to adapt in a fast-paced environment
- Experience in culturing different mammalian cell lines and aseptic techniques
- Ability in prioritization experiments, data analysis, and lab operations
- Exposure to biomaterials and cell encapsulation is a plus
- Previous experience (1-3 years) in biotech/pharma or cell and gene therapy is a plus

About Avenge Bio:

Avenge Bio, Inc. is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte™ platform. The LOCOcyte™ platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor. This initiates a robust, local and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers. Avenge Bio was founded in 2019 based upon technology developed in the laboratory of Omid Veisheh, Ph.D. and has an exclusive license from Rice University for this technology. To learn more, visit www.avengebio.com.

AVENGE BIO, INC | 22 Strathmore Road STE 241, Natick, MA 01760

AVENGE BIO